SCHUCHERT JOSEPH S

Form 4

December 22, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287 January 31,

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Expires: 2005 Estimated average

OMB APPROVAL

Section 16. Form 4 or Form 5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

burden hours per response... 0.5

obligations may continue. See Instruction

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading

Issuer

KELSO PARTNERS V L P

Symbol **ENDO PHARMACEUTICALS**

(Check all applicable)

5. Relationship of Reporting Person(s) to

(Last)

(First)

(Middle)

HOLDINGS INC [ENDP] 3. Date of Earliest Transaction

4. If Amendment, Date Original

Code

Director Officer (give title

10% Owner Other (specify

320 PARK AVENUE

12/21/2005

(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

below)

NEW YORK, NY 10022

(City) (State) (Zip)

(Street)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of	2. Transaction Date	2A. Deemed
Security	(Month/Day/Year)	Execution Date, if
(Instr. 3)		any (Month/Day/Year)

3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of 6. Ownership 7. Nature of Securities Form: Direct Indirect Beneficial Beneficially (D) or Owned Indirect (I) Ownership (Instr. 4) Following (Instr. 4) Reported

I

(A) or Amount (D)

Transaction(s)

(Instr. 3 and 4) Price

Common

Stock, par 12/21/2005 value \$.01

X 236,154 D \$3 15,427,976 by Endo Pharma $LLC_{(2)(3)}$

per share (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orderivative Securities Acquired (A) of Disposed of (I (Instr. 3, 4, and 5)	rivative Expiration Date curities (Month/Day/Year) quired (A) or posed of (D)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Call Obligation (obligation to sell)	\$ 3	12/21/2005		X	236,15	4 11/29/2004	08/26/2007	Common Stock	236,

Reporting Owners

Reporting Owner Name / Address		Relationships					
topoloning of the real time of the second	Director	10% Owner	Officer	Other			
KELSO PARTNERS V L P 320 PARK AVENUE NEW YORK, NY 10022		X					
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
GOLDBERG MICHAEL B C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
Loverro Frank J C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
MATELICH GEORGE E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
SCHUCHERT JOSEPH S C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
WAHRHAFTIG DAVID I C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
WALL THOMAS R IV C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					

Reporting Owners 2

Connors James J II

C/O KELSO & COMPANY 320 PARK AVENUE

X

NEW YORK, NY 10022

Signatures

/s/James J. Connors, II 12/22/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney 11/08/2003

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/09/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of Attorney 11/08/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

James J. Connors, II by Power of

Attorney 11/08/2005

**Signature of Reporting Person Date

Explanation of Responses:

**Signature of Reporting Person

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) Kelso Partners V, L.P. (KP V") is the designated filer.

KP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to secutieties owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

(3)

Signatures 3

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KP V, by virtue of his status as a general partner of the general partner of KP V, and each individual shares investment and voting power along with the other general partners of KP V, but disclaims beneficial ownership of such securities except to the extent of his pecuriary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.